Results 11 to 20 of about 30,153 (204)

Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management [PDF]

Frontiers in Endocrinology, 2021
Aromatase inhibitors (AIs) are a key component in the chemoprevention and treatment of hormone receptor-positive (HR+) breast cancer. While the addition of AI therapy has improved cancer-related outcomes in the management of HR+ breast cancer, AIs are ...
Azadeh Nasrazadani, Adam Brufsky, Brufsky Adam M   +2 more
exaly   +4 more sources

Construction and validation of a risk prediction model for aromatase inhibitor-associated bone loss [PDF]

Frontiers in Oncology, 2023
PurposeTo establish a high-risk prediction model for aromatase inhibitor-associated bone loss (AIBL) in patients with hormone receptor-positive breast cancer.MethodsThe study included breast cancer patients who received aromatase inhibitor (AI) treatment.
Meiling Chu, Yue Zhou, Yulian Yin, Lan Jin, Hongfeng Chen, Tian Meng, Binjun He, Jingjing Wu, Meina Ye   +8 more
doaj   +2 more sources

Managing arthralgia in a postmenopausal woman taking an aromatase inhibitor for hormone-sensitive early breast cancer: a case study

Cancer Management and Research, 2012
Jane Bryce1, Martina Bauer2, Peyman Hadji21National Cancer Institute, Naples, Italy; 2Philipps University of Marburg, Marburg, GermanyBackground: In order to reduce the risk of recurrence, adjuvant treatment with an aromatase inhibitor (AI) is ...
Bryce J, Bauer M, Hadji P
doaj   +1 more source

Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update

Breast Cancer: Targets and Therapy, 2011
Reva Schneider1, Ayman Barakat1, John Pippen1,2,3, Cynthia Osborne1,2,3 1Medical Oncology, Baylor-Sammons Cancer Center, 2Texas Oncology PA, 3US Oncology, Dallas, TX, USA Abstract: Estrogen and its metabolites play a significant role in the proliferation
Schneider RE, Barakat AY, Pippen JE, Osborne CR   +3 more
doaj   +1 more source

Long term effects of aromatase inhibitor treatment in patients with aromatase excess syndrome [PDF]

Frontiers in Endocrinology
IntroductionAromatase excess syndrome (AEXS) is a rare, autosomal dominant disorder, characterized by enhanced aromatization of androgens and estrogen excess.
Eleni Z. Giannopoulou, Eleni Z. Giannopoulou, Stephanie Brandt, Stephanie Brandt, Stephanie Brandt, Stefanie Zorn, Stefanie Zorn, Stefanie Zorn, Christian Denzer, Christian Denzer, Julia von Schnurbein, Julia von Schnurbein, Maki Fukami, Alexander Kaiser, Martin Schmidt, Martin Wabitsch, Martin Wabitsch, Martin Wabitsch   +17 more
doaj   +2 more sources

Clinical utilities of aromatase inhibitors in breast cancer

International Journal of Women's Health, 2015
Saranya Chumsri Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA Abstract: Aromatase is an enzyme that converts testosterones to estrogens.
Chumsri S
doaj   +1 more source

Investigation of aromatase inhibitory activity of metal complexes of 8-hydroxyquinoline and uracil derivatives

Drug Design, Development and Therapy, 2014
Veda Prachayasittikul,1 Ratchanok Pingaew,2 Chanin Nantasenamat,3 Supaluk Prachayasittikul,3 Somsak Ruchirawat,4,5 Virapong Prachayasittikul1 1Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University ...
Prachayasittikul V, Pingaew R, Nantasenamat C, Prachayasittikul S, Ruchirawat S, Prachayasittikul V   +5 more
doaj   +1 more source

The association between endocrine therapy use and osteoporotic fracture among post-menopausal women treated for early-stage breast cancer in Ontario, Canada

Breast, 2021
Background: The use of endocrine therapy for early-stage breast cancer, particularly aromatase inhibitor therapy has been associated with an increased risk of osteoporosis and fracture in clinical trials.
Phillip S. Blanchette, Melody Lam, Britney Le, Lucie Richard, Salimah Z. Shariff, Alexandra M. Ouédraogo, Kathleen I. Pritchard, Jacques Raphael, Ted Vandenberg, Ricardo Fernandes, Danielle N. Desautels, Kelvin K.W. Chan, Craig C. Earle   +12 more
doaj   +1 more source

The HeyL-Aromatase Axis Promotes Cancer Stem Cell Properties by Endogenous Estrogen-Induced Autophagy in Castration-Resistant Prostate Cancer

Frontiers in Oncology, 2022
Treatment of patients with castration-resistant prostate cancer (CRPC) remains a major clinical challenge. We previously showed that estrogenic effects contribute to CRPC progression and are primarily caused by the increased endogenous estradiol produced
Qimei Lin, Jiasong Cao, Jiasong Cao, Xiaoling Du, Kuo Yang, Yongmei Shen, Yongmei Shen, Weishu Wang, Helmut Klocker, Jiandang Shi, Jiandang Shi, Ju Zhang   +11 more
doaj   +1 more source

SERPINA3-ANKRD11-HDAC3 pathway induced aromatase inhibitor resistance in breast cancer can be reversed by HDAC3 inhibition

Communications Biology, 2023
Endocrine resistance is a major challenge for breast cancer therapy. To identify the genes pivotal for endocrine-resistance progression, we screened five datasets and found 7 commonly dysregulated genes in endocrine-resistant breast cancer cells. Here we
Jing Zhou, Mengdi Zhu, Qi Wang, Yiyuan Deng, Nianqiu Liu, Yujie Liu, Qiang Liu   +6 more
doaj   +1 more source